Status:
UNKNOWN
Role of Octreotide in Non Variceal Bleeding
Lead Sponsor:
National Hepatology & Tropical Medicine Research Institute
Conditions:
Non-variceal Gastrointestinal Bleeding
Eligibility:
All Genders
18+ years
Phase:
PHASE2
PHASE3
Brief Summary
The rationale for using somatostatin (octreotide0 is that it has been shown to inhibit the secretion of various gastrointestinal hormones, including gastrin and secretin, which can contribute to the d...
Detailed Description
All patients admitted will receive the routine monitoring for the vital signs and supportive treatment. Resuscitation of a hemodynamically unstable patient begins with assessing and addressing the "AB...
Eligibility Criteria
Inclusion
- The subjects are adults aged ≥18years old
- admitted to the intensive care unit of the National hepatology and Tropical Medicine Research institute and Alexandria university presenting with acute non-variceal gastrointestinal bleeding
Exclusion
- If they have variceal bleeding
- received active endoscopic treatment (e.g. hemoclips or monopolar coagulation)
- known hypersensitivity to somatostatin analogue (octreotide) or any of its components
- pregnancy or breastfeeding
- active malignancy
- and use of somatostatin analogue within the past 7 day.
Key Trial Info
Start Date :
August 23 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
January 1 2025
Estimated Enrollment :
56 Patients enrolled
Trial Details
Trial ID
NCT06062719
Start Date
August 23 2023
End Date
January 1 2025
Last Update
October 2 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
NHTMRI
Cairo, Egypt, 4260010